Constellation announces that a new minimally invasive surgical device – TAGSS has been recommended for CE mark. This innovative new device allows surgeons to perform novel and advanced hybrid procedures combining laparoscopy and GI endoscopy.
Constellation is a French consortium of privately held companies founded in 2016 and located in Strasbourg, France. PROTOMED SA (Strasbourg), IHU- STRASBOURG and BS MEDICAL TECH (Niederroedern), founders of Constellation, gather together years of expertise in medical device R&D, clinical expertise, testing, training and manufacturing. Constellation offers to medical device companies a unique range of services from development of 1 st prototypes to market release. It manages customer’s development projects in house but also with various partners and acts as a single point of contact for the customer.
TAGGS : allows surgeons to perform novel and advanced hybrid procedures
ENDOTAGSS LLC, a US based start-up, was attracted by these unique services and has decided to rely on CONSTELLATION to develop its medical devices including TAGSS. The first of its kind, TAGSS offers a direct access to the stomach for surgeons who want to perform hybrid surgeries. Placed by flexible endoscopy, it allows surgeons and gastroenterologists to introduce rigid laparoscopic instruments through TAGSS ports and enables collaboration between flexible endoscopic tools introduced through the mouth and laparoscopic tools through the TAGSS. This will help surgeons develop new therapeutic strategies for intragastric diseases.
A first milestone for Constellation
TAGSS is the 1st project of Constellation to reach the market, and thanks to its privileged location in the Nextmed and the support of local authorities and Biovalley France, Constellation is already working with additional customers in Europe, USA and the middle East to develop new minimally invasive devices.
“Endotagss was a small team of innovative clinical professionals. They needed to have R&D and regulatory support, that was the part of Protomed; Preclinical validation, where IHU Strasbourg excels and a manufacturing capacity for clinical products, in line with BS MEDICAL TECH expertise”
says Frédéric Mouret, Protomed’s CEO. Professor Lee Swanström, Chief Innovations officer and Scientific Director of the IHU-Strasbourg adds :
“We are proud to be a part of CONSTELLATION and consider it a critical expression of the IHU mandate to develop innovative surgical tools. The TAGSS project is validation that Strasbourg is truly a world center for medical innovation thanks to the pooled expertise of groups like CONSTELLATION.”
Today, the notification certificate is expected to be sent to ENDOTAGGS LLC shortly and discussions are underway with a first center in Germany.
Congratulations to this new star of Strasbourg !
For more information about Constellation, you can contact Frederic Mouret :
+33 3 67 17 67 23 – f.mouret@protomed.fr – http://medicaldevicedevelopment.services